Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female over 20 years of age.~* Clinical diagnosis of advanced SMD.~* The visual acuity of the eye to receive the transplant will be no better than hand movement.~* The visual acuity of the eye that is not to receive the transplant will be no better than 24 (20/320) Early Treatment of Diabetic Retinopathy Study (ETDRS) letters.~Exclusion Criteria:~* History of malignancy.~* History of myocardial infarction in previous 12 months.~* History of diabetes mellitus.~* Any immunodeficiency.~* Any current immunosuppressive therapy other than intermittent or low dose cortico steroids.~* Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.~* Current participation in any other clinical trial.~* Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.~* Any other sight-threatening ocular disease.~* Any chronic ocular medications. Any history of retinal vascular disease (compromised blood-retinal barrier). Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MA09-hRPE administration (Type: EXPERIMENTAL): Biological: MA09-hRPE Cellular therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).